Helping you stay current in drug monitoring


Pandemic Brings Drop in Testing, Increase in Illicit Drugs

Clinical drug testing fell by over 50% in spring of 2020 due to the COVID-19 pandemic, according to a new study from Quest Diagnostics®. At the same time, the proportion of samples testing positive for dangerous illicit drugs and drug combinations rose.

Dec 31 2020

Drugs with Highest Rates of Positivity in the Workforce

In mandated tests of employees in safety-sensitive jobs, marijuana had the highest rate of drug positivity, followed by opioids and amphetamines, according to the 2020 Quest Diagnostics Drug Testing Index™ report. The report includes data from over 2.4 million tests from January to December 2019 of workers in safety-sensitive positions undergoing federally mandated drug tests. These include workers in the airline, transportation, and marine industries, among others.

Dec 28 2020

Fewer Tests from MAT Facilities During Pandemic

The COVID-19 pandemic appears to have reduced the number of patients receiving treatment at medication-assisted treatment (MAT) facilities, according to data from a new study from Quest Diagnostics analyzing clinical drug test results before and during the pandemic.

Dec 17 2020

Gabapentin Positivity Declined During the Pandemic

While non-prescribed use of several drugs, including fentanyl, increased with the onset of the COVID-19 pandemic, non-prescribed use of gabapentin fell, according to a new study from Quest Diagnostics®. The study compared non-prescribed prescription and illicit drug positivity before and during the pandemic.

Dec 11 2020